Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection

详细信息    查看全文

• 作者：Huei-Ru Cheng (1)
  Jia-Horng Kao (1) (2) (3) (4)
  Hui-Lin Wu (1) (3)
  Tai-Chung Tseng (5)
  Chen-Hua Liu (2) (3)
  Hung-Chih Yang (2)
  Tung-Hung Su (2) (3)
  Pei-Jer Chen (1) (2) (3) (4)
  Ding-Shinn Chen (1) (2) (3)
  Chun-Jen Liu (1) (2) (3)
  
  1. Graduate Institute of Clinical Medicine ; National Taiwan University College of Medicine and National Taiwan University Hospital ; 1 Chang-Te Street ; Taipei ; 10002 ; Taiwan
  2. Department of Internal Medicine ; National Taiwan University College of Medicine and National Taiwan University Hospital ; Taipei ; Taiwan
  3. Hepatitis Research Center ; National Taiwan University College of Medicine and National Taiwan University Hospital ; 1 Chang-Te Street ; Taipei ; 10002 ; Taiwan
  4. Department of Medical Research ; National Taiwan University College of Medicine and National Taiwan University Hospital ; Taipei ; Taiwan
  5. Department of Internal Medicine ; Buddhist Tzu Chi General Hospital ; Taipei Branch ; Taipei ; Taiwan
  
• 关键词：miR ; 122 ; HBV ; HCV dual infection ; HBsAg
• 刊名：Hepatology International
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：9
• 期：1
• 页码：35-42
• 全文大小：243 KB
• 参考文献：1. Liu CJ, Liou JM, Chen DS, Chen PJ. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 2005;104:783鈥?91
  2. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157:674鈥?82
  3. Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011;54:381鈥?92
  4. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011;29:3643鈥?650
  5. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009;136:496鈥?04
  6. Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Treatment of patients with dual hepatitis C and B by peginterferonalfa and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 2014;63:506鈥?14
  7. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. Hepatology 2006;43:100鈥?07
  8. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15:133鈥?43
  9. Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc 2013;112:302鈥?11
  10. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. REVEAL-HBV Study Group. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010;139:474鈥?82
  11. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517 e2鈥?25 e2
  12. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen鈥搉egative patients with a low viral load. Hepatology 2012;55:68鈥?6
  13. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int 2009;3:517鈥?25
  14. Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology 2011;53:1839鈥?845
  15. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37:568鈥?76
  16. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004;126:1024鈥?029
  17. Tseng FC, Edlin BR, Zhang M, Kral A, Busch MP, Ortiz-Conde BA, et al. The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepatol 2008;15:690鈥?98
  18. Yu ML, Lee CM, Chuang WL, Lu SN, Dai CT, Chu CM, et al. HBsAg profiles in patients receiving peginterferonalfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010;202:86鈥?2
  19. Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, et al. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One 2013;8:e53008
  20. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010;84:6615鈥?625
  21. Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010;398:771鈥?77
  22. Cullen BR. Viruses and microRNAs. Nat Genet 2006;38:S25鈥揝30
  23. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735鈥?39
  24. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008;48:648鈥?56
  25. Moore KJ, Rayner KJ, Su谩rez Y, Fern谩ndez-Hernando C. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr 2011;31:49鈥?3
  26. Waidmann O, K枚berle V, Brunner F, Zeuzem S, Piiper A, Kronenberger B. Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One 2012;7:e45652
  27. Li C, Wang Y, Wang S, Wu B, Hao J, Fan H, et al. Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol 2013;87:2193鈥?205
  28. Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, et al. Epigenetic regulation of miR-122 by PPAR纬 and hepatitis B virus X protein in hepatocellular carcinoma cells. Hepatology 2013;58:1681鈥?692
  29. van der Meer AJ, Farid WR, Sonneveld MJ, Sonneveld MJ, de Ruiter PE, Boonstra A, et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 2013;20:158鈥?66
  30. Su TH, Liu CH, Liu CJ, Chen CL, Ting TT, Tseng TC, et al. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci USA 2013;110:7844鈥?849
  31. Chen Y, Shen A, Rider PJ, Yu Y, Wu K, Mu Y, et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011;25:4511鈥?521
  32. Wang S, Qiu L, Yan X, Yu Y, Wu K, Mu Y, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity. Hepatology 2012;55:730鈥?41
  33. Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012;19:e58鈥揺65
  34. Arataki K, Hayes CN, Akamatsu S, Akiyama R, Abe H, Tsuge M, et al. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol 2013;85:789鈥?98
  35. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010;56:1830鈥?838
  36. Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2011;15:1133鈥?139
  37. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011;106:1663鈥?669
  38. Hayes CN, Akamatsu S, Tsuge M, Miki D, Akiyama R, Abe H, et al. Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle. PLoS One 2012;7:e47490
  39. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108:5003鈥?008
  
• 刊物主题：Hepatology; Colorectal Surgery; Surgery;
• 出版者：Springer India
• ISSN：1936-0541

文摘

Background The clinical significance of serum microRNA-122 (miR-122) has been shown in viral hepatitis B and C, respectively. Specifically, miR-122 stimulates hepatitis C virus (HCV) replication but suppresses hepatitis B virus (HBV) replication. The profile and clinical significance of serum miR-122 in patients with dual chronic hepatitis B and C would be an interesting and important clinical issue. Methods A total of 76 patients with HBV/HCV dual infection, 105 with HCV monoinfection and 39 with HBV monoinfection were enrolled. All patients received peginterferon alfa-2a (PEG-IFN)-based treatment. Serum miR-122 levels were quantified by using a sensitive hybridization-based assay. Results At baseline, the serum miR-122 level was lower in HCV-monoinfected patients than in HBV-monoinfected patients, whereas HBV coinfection increased the expression of miR-122. In multivariate analysis, the serum miR-122 level was positively correlated with the serum HBsAg level in patients with HBV/HCV dual infection and those with HBV monoinfection. In dually infected patients who received PEG-IFN-based treatment, a high baseline miR-122 level was positively correlated with a greater reduction of the posttreatment serum HBsAg level. Conclusion In summary, the serum miR-122 level is highly correlated with the HBsAg level in HBV/HCV dually infected patients and may serve as a biomarker to predict posttreatment HBsAg decline.